Germline Homologous Recombination Repair (HRR) Test

Test Code
SLS161014
Book Now

What is the Germline HRR Test?

The Germline Homologous Recombination Repair (HRR) Test analyzes genes involved in DNA damage repair pathways, particularly homologous recombination, a critical mechanism for maintaining genomic stability. Mutations in HRR genes impair the ability of cells to repair double-strand DNA breaks, increasing cancer susceptibility. Defective HRR is a key driver of tumorigenesis in several cancers, including ovarian, prostate, pancreatic, and breast cancers.

This test is particularly significant because HRR deficiency (HRD) is predictive of response to PARP inhibitors (e.g., olaparib, rucaparib, talazoparib), a class of targeted therapies that exploit DNA repair deficiencies to selectively kill cancer cells.

Genes Covered/No of Genes: 14 Genes

Indications for Testing

  • Patients with cancers that may be responsive to PARP inhibitors (breast, ovarian, prostate, pancreatic).
  • Individuals with a personal or family history of DNA repair deficiency-related cancers, like breast, ovarian, prostate, pancreatic.
  • To assess prognosis and treatment response in HR-deficient tumors.

Inheritance Pattern

Autosomal dominant—HRR gene defects impair DNA repair, increasing cancer susceptibility.

Why is This Test Important?

HRR testing helps identify patients who may benefit from targeted treatments like PARP inhibitors.
Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Biliary Duct Cancer, Lung Cancer

Contact Us